124. 皮質下梗塞と白質脳症を伴う常染色体優性脳動脈症 Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy Clinical trials / Disease details
臨床試験数 : 12 / 薬物数 : 14 - (DrugBank : 5) / 標的遺伝子数 : 3 - 標的パスウェイ数 : 11
Showing 1 to 10 of 12 diseases
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | JPRN-jRCTs051220072 | 09/08/2022 | 09/08/2022 | Effect of Lomerizine Hydrochloride on Preventing Recurrence of Cerebral Ischemic Events in Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy Effect of Lomerizine Hydrochloride on Preventing Recurrence of Cerebral Ischemic Events in Cerebral ... | Effect of Lomerizine Hydrochloride on Preventing Recurrence of Cerebral Ischemic Events in Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy - LOMCAD Effect of Lomerizine Hydrochloride on Preventing Recurrence of Cerebral Ischemic Events in Cerebral ... | Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL) CADASIL;D046589 Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy(CADASIL) ... | Lomerizine hydrochloride (MIGSYS tablets 5 mg, 1 tablet twice daily) will be administered continuously for 24 months as the study drug. Lomerizinehydrochloride (MIGSYS tablets 5 mg, 1 tablet twice daily) will be administered continuousl ... | Mizuno Toshiki | NULL | Recruiting | >= 20age old | <= 70age old | Both | 20 | N/A | Japan |
| 2 | NCT04334408 (ClinicalTrials.gov) | December 2021 | 2/4/2020 | Safety and Efficacy of Fremanezumab for Migraine in Adult CADASIL | A Phase II Double-Blinded Placebo Controlled Individual Subject Stepped Wedge Clinical Trial Evaluating the Safety and Efficacy of Fremanezumab for Migraine in Adult CADASIL A Phase II Double-Blinded Placebo Controlled Individual Subject Stepped Wedge Clinical Trial Evaluat ... | Cadasil;Migraine | Drug: Fremanezumab;Drug: Placebo | Mayo Clinic | NULL | Not yet recruiting | 18 Years | 70 Years | All | 5 | Phase 2 | United States |
| 3 | NCT04658823 (ClinicalTrials.gov) | December 21, 2020 | 29/11/2020 | Efficacy and Safety of Tocotrienols in CADASIL | A Randomized Placebo-controlled Double-blind Pilot / Phase II Study to Assess the Efficacy and Safety of HOV-12020 in Patients With Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy (CADASIL) A Randomized Placebo-controlled Double-blind Pilot / Phase II Study to Assess the Efficacy and Safet ... | Cadasil | Drug: HOV-12020 (Palm tocotrienols complex);Drug: Placebo | Hovid Berhad | NULL | Active, not recruiting | 45 Years | 75 Years | All | 50 | Phase 2 | France |
| 4 | NCT01361763 (ClinicalTrials.gov) | June 2011 | 16/5/2011 | Safety Study of Dabigatran in CADASIL | Phase II, Randomized, Crossover, Single Blind, Safety Trial of DABIGATRAN Versus ASA for Preventing Ischaemic Brain Lesions in Patients Affected by CADASIL Phase II, Randomized, Crossover, Single Blind, Safety Trial of DABIGATRAN Versus ASA for Preventing ... | CADASIL | Drug: Dabigatran;Drug: Antiplatelets | S. Andrea Hospital | NULL | Recruiting | 18 Years | N/A | Both | 50 | Phase 2 | Italy |
| 5 | EUCTR2007-004370-55-IT (EUCTR) | 14/12/2007 | 11/12/2007 | Effects of tetrahydrobiopterin (6R-BH4) on flow-mediated dilation in CADASIL patients: a randomised controlled trial - CADASIL BH4 Effects of tetrahydrobiopterin (6R-BH4) on flow-mediated dilation in CADASILpatients: a randomised c ... | Effects of tetrahydrobiopterin (6R-BH4) on flow-mediated dilation in CADASIL patients: a randomised controlled trial - CADASIL BH4 Effects of tetrahydrobiopterin (6R-BH4) on flow-mediated dilation in CADASILpatients: a randomised c ... | CADASIL (Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy), is a rare autosomal dominant disorder characterized by recurrent strokes starting in mid-adulthood and leading in some to severe motor disability with pseudobulbar palsy and dementia of the subcortical type MedDRA version: 9.1;Level: HLGT;Classification code 10008804;Term: Chromosomal abnormalities and abnormal gene carriers CADASIL(Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy), ... | Product Name: Phenoptin Product Code: 6R-BH4 INN or Proposed INN: sapropterin | AZIENDA OSPEDALIERA OSPEDALE NIGUARDA CA' GRANDA (A.O. DI RILIEVO NAZIONALE) | NULL | Not Recruiting | Female: yes Male: yes | Italy | ||||
| 6 | EUCTR2004-001162-40-IT (EUCTR) | 05/04/2005 | 21/09/2005 | An 18-Week, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Of The Efficacy, Safety, And Tolerability Of Donepezil HCl (E2020) In Patients With CADASIL Who Have Cognitive Impairment. An 18-Week, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Of The ... | An 18-Week, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Of The Efficacy, Safety, And Tolerability Of Donepezil HCl (E2020) In Patients With CADASIL Who Have Cognitive Impairment. An 18-Week, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Of The ... | Donezepil HCl for treatment of patients with CADASIL (Cerebral autosomal dominant arteriopathy with subcortical infracts and leukoencephalopathy) who have cognitive impairment. MedDRA version: 6.1;Level: PT;Classification code 10009843 Donezepil HCl for treatment of patients with CADASIL(Cerebral autosomal dominant arteriopathy with s ... | Trade Name: ARICEPT 5*28 CPR 5 MG Product Name: NA Product Code: NA INN or Proposed INN: Donepezil | EISAI LTD UK | NULL | Not Recruiting | Female: yes Male: yes | Finland;United Kingdom;Germany;Spain;Italy;Sweden | ||||
| 7 | EUCTR2004-001162-40-SE (EUCTR) | 01/04/2005 | 03/02/2005 | An 18-week, multi-center, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of donepezil HCl (E2020) in patients with CADASIL who have cognitive impairment. - Donepezil HCl in CADASIL An 18-week, multi-center, randomized, double-blind, placebo-controlled, parallel-group study of the ... | An 18-week, multi-center, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of donepezil HCl (E2020) in patients with CADASIL who have cognitive impairment. - Donepezil HCl in CADASIL An 18-week, multi-center, randomized, double-blind, placebo-controlled, parallel-group study of the ... | Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL).CADASIL is a genetic disorder representing a minority of the patients who develop vascular dementia. MedDRA version: 7.0;Level: PT;Classification code 10057678 Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy(CADASIL). ... | Trade Name: Aricept Product Name: Aricept Product Code: E2020 INN or Proposed INN: donepezil hydrochloride Trade Name: Aricept Product Name: Aricept Product Code: E2020 INN or Proposed INN: donepezilhydrochlori ... | Eisai Ltd | NULL | Not Recruiting | Female: yes Male: yes | 150 | Finland;United Kingdom;Germany;Spain;Italy;Sweden | |||
| 8 | EUCTR2004-001162-40-ES (EUCTR) | 29/03/2005 | 20/01/2006 | An 18-week, multi-center, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of donepezil HCl (E2020) in patients with CADASIL who have cognitive impairment. - Donepezil HCl in CADASIL An 18-week, multi-center, randomized, double-blind, placebo-controlled, parallel-group study of the ... | An 18-week, multi-center, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of donepezil HCl (E2020) in patients with CADASIL who have cognitive impairment. - Donepezil HCl in CADASIL An 18-week, multi-center, randomized, double-blind, placebo-controlled, parallel-group study of the ... | Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL). CADASIL is a genetic disorder representing a minority of the patients who develop vascular dementia. MedDRA version: 7.0;Level: PT;Classification code 10057678 Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy(CADASIL) ... | Trade Name: Aricept Product Name: Aricept Product Code: E2020 INN or Proposed INN: donepezil hydrochloride Trade Name: Aricept Product Name: Aricept Product Code: E2020 INN or Proposed INN: donepezilhydrochlori ... | Eisai Ltd | NULL | Not Recruiting | Female: yes Male: yes | 150 | Human pharmacology (Phase 1): Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): Therapeutic use (Phase 4): Human pharmacology (Phase 1): Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Pha ... | Finland;Spain;Germany;Italy;United Kingdom;Sweden | ||
| 9 | EUCTR2004-001162-40-FI (EUCTR) | 08/03/2005 | 28/12/2004 | An 18-week, multi-center, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of donepezil HCl (E2020) in patients with CADASIL who have cognitive impairment. - Donepezil HCl in CADASIL An 18-week, multi-center, randomized, double-blind, placebo-controlled, parallel-group study of the ... | An 18-week, multi-center, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of donepezil HCl (E2020) in patients with CADASIL who have cognitive impairment. - Donepezil HCl in CADASIL An 18-week, multi-center, randomized, double-blind, placebo-controlled, parallel-group study of the ... | Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL).CADASIL is a genetic disorder representing a minority of the patients who develop vascular dementia. MedDRA version: 7.0;Level: PT;Classification code 10057678 Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy(CADASIL). ... | Trade Name: Aricept Product Name: Aricept Product Code: E2020 INN or Proposed INN: donepezil hydrochloride Trade Name: Aricept Product Name: Aricept Product Code: E2020 INN or Proposed INN: donepezilhydrochlori ... | Eisai Ltd | NULL | Not Recruiting | Female: yes Male: yes | 150 | Phase 2 | Finland;Spain;Germany;Italy;United Kingdom;Sweden | ||
| 10 | EUCTR2004-001162-40-GB (EUCTR) | 24/02/2005 | 23/02/2005 | An 18-week, multi-center, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of donepezil HCl (E2020) in patients with CADASIL who have cognitive impairment. - Donepezil HCl in CADASIL An 18-week, multi-center, randomized, double-blind, placebo-controlled, parallel-group study of the ... | An 18-week, multi-center, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of donepezil HCl (E2020) in patients with CADASIL who have cognitive impairment. - Donepezil HCl in CADASIL An 18-week, multi-center, randomized, double-blind, placebo-controlled, parallel-group study of the ... | Cerebral autosomal dominant arteriopathy with subcortical infracts and leukoencephalopathy (CADASIL). CADASIL is a genetic disorder representing a minority of the patients who develop vascular dementia. MedDRA version: 7.0;Level: PT;Classification code 10057678 Cerebral autosomal dominant arteriopathy with subcortical infracts and leukoencephalopathy (CADASIL) ... | Trade Name: Aricept Product Name: Aricept Product Code: E2020 INN or Proposed INN: donepezil hydrochloride Trade Name: Aricept Product Name: Aricept Product Code: E2020 INN or Proposed INN: donepezilhydrochlori ... | Eisai Ltd | NULL | Not Recruiting | Female: yes Male: yes | 150 | Human pharmacology (Phase 1): Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): Therapeutic use (Phase 4): Human pharmacology (Phase 1): Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Pha ... | Finland;Spain;Germany;Italy;United Kingdom;Sweden |